NCT06747832

INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer

A Single-center, Single-arm Clinical Study of the Efficacy and Safety of INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer

• Status: Enrolling By Invitation
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Guangzhou Ruixin Biotechnological Co., LTD · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a clinical study on the use of iNK cells for the treatment of small cell lung cancer.

Detailed description

Natural killer (NK) cells are lymphocytes of the innate immune system and could recognize and kill a wide range of cells in distress, particularly tumour cells and cells infected with viruses. Induced pluripotent setm cells(iPSCs) derived NK cells have better proliferative capacity and homogeneity than donor peripheral blood or umbilical cord blood derived NK cells. The investigators conduct this clinical study to evaluate the efficacy and safety of INK cells as maintenance therapy after chemoradiotherapy for small cell lung cancer and The purpose of investigators is to find new treatment option.

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	iNK cells	Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.

Timeline

• Start date: 2024-12-15
• Primary completion: 2026-06-14
• Completion: 2026-12-14
• First posted: 2024-12-24
• Last updated: 2024-12-24

Locations

1 site across 1 country: China